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Early changes in emotional processing as a marker of clinical
response to SSRI treatment in depression
BR Godlewska1, M Browning2, R Norbury3, PJ Cowen1 and CJ Harmer2
Antidepressant treatment reduces behavioural and neural markers of negative emotional bias early in treatment and has been
proposed as a mechanism of antidepressant drug action. Here, we provide a critical test of this hypothesis by assessing whether
neural markers of early emotional processing changes predict later clinical response in depression. Thirty-five unmedicated patients
with major depression took the selective serotonin re-uptake inhibitor (SSRI), escitalopram (10 mg), over 6 weeks, and were
classified as responders (22 patients) versus non-responders (13 patients), based on at least a 50% reduction in symptoms by the
end of treatment. The neural response to fearful and happy emotional facial expressions was assessed before and after 7 days
of treatment using functional magnetic resonance imaging. Changes in the neural response to these facial cues after 7 days of
escitalopram were compared in patients as a function of later clinical response. A sample of healthy controls was also assessed. At
baseline, depressed patients showed greater activation to fear versus happy faces than controls in the insula and dorsal anterior
cingulate. Depressed patients who went on to respond to the SSRI had a greater reduction in neural activity to fearful versus happy
facial expressions after just 7 days of escitalopram across a network of regions including the anterior cingulate, insula, amygdala
and thalamus. Mediation analysis confirmed that the direct effect of neural change on symptom response was not mediated by
initial changes in depressive symptoms. These results support the hypothesis that early changes in emotional processing with
antidepressant treatment are the basis of later clinical improvement. As such, early correction of negative bias may be a key
mechanism of antidepressant drug action and a potentially useful predictor of therapeutic response.
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INTRODUCTION
Major depression is associated with a range of negative biases in
the processing of emotional information.1 For example, compared
with healthy controls, depressed patients selectively recall more
negative, self-related emotional information in memory tasks and
demonstrate negative biases in the perception of social signals
such as emotional facial expressions.2,3 Such biases have been
associated with aberrant responses across a network of neural
areas involved in emotional processing. Untreated patients with
depression show enhanced reactivity to negative stimuli in
networks involved in emotional salience and attention such as
the amygdala, visual cortex, insula and thalamus as well as
differences in response in areas thought to have a role in emotion
monitoring, evaluation and regulation including the anterior
cingulate (ACC) and dorsolateral prefrontal cortex.4–7 These
negative biases appear to have a key role in the pathophysiology
and maintenance of depressive states.1
We have proposed that the therapeutic effect of antidepressant
drugs is mediated by early reversal of these negative emotional
biases.8 For example, in healthy volunteers, 7 days' treatment with
the selective serotonin re-uptake inhibitor (SSRI), citalopram, and
the selective noradrenaline re-uptake inhibitor, reboxetine,
diminished the recognition of negative emotional faces, increased
recall of positive self-referential words and attenuated the
amygdala response to fearful faces as measured by functional
magnetic resonance imaging (fMRI).9–11 Studies in depressed
patients have also shown attenuation of the neural response to
sad and fearful faces after antidepressant treatment in limbic areas
including the amygdala, insula and ACC.4,7,12 However, these
studies have typically been conducted after 6–8 weeks of therapy,
by which time clinical response is well established. As such, it is
difficult to assess whether changes in neural responsivity are a
cause or effect of changes in depression symptoms.
To address this question, we recently assessed the effects of
just 7 days' treatment with the SSRI, escitalopram (10 mg), in
depressed patients using a double-blind, placebo-controlled
study.13 Amygdala response to fearful versus happy faces was
normalised following escitalopram relative to placebo treatment
before any significant clinical response. Such early changes in
processing may have a critical role in the emergence of clinical
therapeutic effects over time as the patient responds to the
reduced impact of negative events, stressors and cues.8 Early
changes in information processing were seen in both behavioural
and fMRI studies, and may lead to a gradual change in clinical
symptomatology through interaction with on-going environmen-
tal and social stimuli.
If this hypothesis of antidepressant action is correct, we would
expect early changes in emotional processing to be predictive of
later clinical response to SSRI therapy in depression. The current
study tested this critical hypothesis using a functional neuroima-
ging emotional paradigm. We predicted that a greater reduction
in the neural response to fearful versus happy facial expressions
1Psychopharmacology Research Unit, University Department of Psychiatry, University of Oxford, Oxford, UK; 2Psychopharmacology and Emotion Research Laboratory, University
Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK and 3Department of Psychology, Whitelands College, University of Roehampton, London, UK.
Correspondence: Professor CJ Harmer, Psychopharmacology and Emotion Research Laboratory, University Department of Psychiatry, Warneford Hospital, University of Oxford,
Oxford OX3 7JX, UK.
E-mail: catherine.harmer@psych.ox.ac.uk
Received 24 December 2015; revised 19 May 2016; accepted 1 June 2016
Citation: Transl Psychiatry (2016) 6, e957; doi:10.1038/tp.2016.130
www.nature.com/tp
across a network of previously identified brain areas, including the
amygdala, insula and cingulate cortex, after 1 week of treatment
would be associated with an increased response to treatment at
week 6. We did not use placebo treatment because of ethical
concerns about giving placebo for 6 weeks to depressed patients.
In addition, our above-mentioned study13 showed that after
7 days of treatment with escitalopram the amygdala activity in
depressed patients was similar to that in healthy controls, whereas
placebo produced no such effect. Healthy controls were included
to show baseline differences between the tested groups, and to
explore whether there were differences between controls and
responders and non-responders.
MATERIALS AND METHODS
Participants
Thirty-five participants (20 F:15M) with major depression completed the
fMRI and treatment protocol (see Table 1). An additional four patients
consented to take part, but dropped out before the end of the 6-week
period of treatment (two after the first session and two before the 6-week
assessment). Thirty-one healthy control participants completed baseline
scans; however, data from two participants were lost because of computer
error, leaving a sample of 29 (17 F:12M). All participants were assessed for
the presence of current and past psychiatric disorder with the Structured
Clinical Interview for DSM-IV14. The depressed patients met the criteria for
a primary diagnosis of major depressive disorder; the control participants
had no current or lifetime diagnosis. Exclusion criteria for the study
included psychosis or substance dependence as defined by DSM-IV, being
at clinically significant risk of suicidal behaviour, having contraindications
to escitalopram treatment or being treated with psychotropic medication
less than 3 weeks before the study (5 weeks for fluoxetine). We also
excluded patients with major somatic or neurological disorders, who were
pregnant or breast-feeding, with any contraindications to MRI or
concurrent medication, which could alter emotional processing. All
participants were right-handed. The study was approved by the Oxford
Research Ethics Committee, and all participants gave written informed
consent.
Study design and drug treatment
The sample of patients (n= 35) and healthy controls (n=29) were assessed
at baseline. Patients received 10 mg escitalopram each morning for a
period of 6 weeks without dose adjustment. In the patient group,
assessment of depressive severity and treatment response was made using
the Hamilton Depression Rating Scale (HAM-D),15 Beck Depression
Inventory (BDI)16 and Spielberger’s State-Trait Anxiety inventory (STAI)17
at baseline, week 1 and week 6. The fMRI assessments were completed at
the same time points. The current analysis focuses on the degree to which
early changes (between baseline and week 1) in the function of emotional
processing systems was able to predict clinical response at week 6 in the
depressed patients. After the 6-week duration of the study, all patients
were offered treatment openly with escitalopram according to usual
clinical practice (data not captured). Clinical response to the SSRI was
defined as a reduction in HAM-D of 50% or more from baseline after
6 weeks of treatment.18 Healthy controls were assessed at baseline only
with HAM-D, BDI and STAI, and had a single fMRI scan performed at the
same time.
fMRI data acquisition
fMRI data were acquired on a 3 T Siemens TIM TRIO (Siemens, Erlangen,
Germany). Data were acquired with a voxel resolution of 3 × 3× 3.5 mm,
repetition time (TR)/ echo time (TE)/ flip angle = 2000 ms/28ms/89o. A total
of 256 volumes were acquired in an experiment lasting 8.5 min. T1-
weighted structural images were acquired using a magnetisation-prepared
rapid acquisition by gradient echo sequence with a voxel resolution
1.0 × 1.0 × 1.0 mm on a 208× 256× 200 grid, TE/ inversion time/TR= 4.68
/900/2040 ms. To monitor cardiac and respiratory processes, subjects wore
a pulse oximeter and respiratory bellows.
fMRI experimental task
During fMRI scanning, participants completed a well-validated gender
discrimination task involving the rapid presentation of fearful and happy
faces.12 This task, which involves passive processing of emotional
information, under the form of fearful and happy faces, with minimal
attentional effort, provides an incidental measure of emotional processing
and is believed to be a better probe of limbic function.19 In this task, nine
30-s blocks of a baseline fixation cross were interleaved with eight 30-s
blocks of the emotional task (four blocks of fear and four blocks of happy).
Each face was presented for 100 ms, and the subjects were asked to report
the gender of the face via an MRI-compatible key pad.
fMRI preprocessing and statistical analysis
fMRI data were preprocessed and analysed using FMRIB Software Library
(FSL).20 Briefly, motion correction was applied using a rigid body
registration to the central volume; the brain matter was segmented from
non-brain using a mesh deformation approach. Gaussian spatial smooth-
ing was applied with a full-width half-maximum of 5 mm; high-pass
temporal filtering was applied using a Gaussian-weighted running line
filter, with a 3 dB cutoff of 120 s.
A general linear model was fitted in pre-whitened data space. Two
explanatory variables (plus their temporal derivatives) were modelled: ‘fear
faces’ and ‘happy faces’. All explanatory variables were convolved with a
default haemodynamic response function (Gamma function, delay = 6 s, s.
d. = 3 s), and filtered by the same high-pass filter as the data. The impact of
physiological noise on the BOLD signal was reduced using the
Physiological Noise Modelling tool of FSL. Pulse oximetry and respiratory
bellows' data were processed by Physiological Noise Modelling to create
Table 1. Clinical and demographic data for week 6 responders (⩾50% decrease in HAM-D scores) versus non-responders (o50% decrease in HAM-D
scores)
Responders Non-responders Responders versus
non-responders
Healthy volunteers Patients versus
healthy controls
Gender (F:M) 12:10 8:5 0.163, P= 0.686 17:12 0.014, P= 0.905
Age (mean (s.d.)) 30 (11.5, 20–61) 30.1 (10, 20–52) 0.000, P= 0.984 30 (9.6, 19–58) 0.004, P= 0.949
Trait anxiety (mean (s.d., range)) 59.4 (8.7, 43–74) 63.3 (10.3, 61–74) 1.427, P= 0.421 29.6 (7.8, 20–44) 203.9, Po0.000
HAM-D (mean (s.d., range)) 23.1 (4.9, 14–32) 22.9 (4, 14–29) 0.006, P= 0.939 0.4 (0.8, 0–3) 707.4, Po0.000
BDI (mean (s.d., range)) 31.6 (6.7, 19–49) 32.4 (5.3–40) 0.147, P= 0.704 0.9 (1.5, 0–5) 691.5, Po0.000
Week 1 change in HAM-D (mean (s.d.)) –5 (6.8) − 1.9 (3.4) 2.373, P= 0.133
Week 6 reduction in trait anxiety –13.4 (12.4) − 6.4 (10.8) 2.834, P= 0.102
Length of current episode (in months) 5.9 (6.0) 8.8 (8.7) 1.369, P= 0.250
Number of antidepressant-naive 8/22 6/13 0.326, P= 0.568
Abbreviations: ANOVA, analysis of variance; BDI, Beck Depression Inventory; HAM-D, Hamilton Depression Rating Scale; STAI, Spielberger’s State-Trait Anxiety
inventory. Treatment resistance defined as a failure to respond to adequate courses (in terms of length and dose) of at least two antidepressants from different
classes). Continuous variables are shown as mean (s.d.). There are no statistically significant differences between responders and non-responders. Gender and
number of antidepressant-naive were performed using χ2-tests, all other comparisons suing ANOVA. Patients and controls differed in terms of clinical scores
(BDI, HAM-D and STAI-T; all P= 0.000), although there were no differences in terms of gender and age.
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33 nuisance regressors that were added to the first-level fMRI model. The
full model was simultaneously regressed against the BOLD data, giving the
best-fitting amplitudes for each explanatory variable while accounting for
the physiological noise.
The task contrast of interest in this study was the relative activation of
fearful versus happy faces. The degree to which the change in neural
activity in this contrast, induced by 1 week of SSRI treatment, predicted
participants’ clinical response on the HAM-D to medication over 6 weeks
was tested using a three-level analysis. The first level consisted of the
fearful versus happy contrast maps, as described above, calculated for each
depressed subject and each visit. Second-level, fixed effects analyses
calculated the degree to which these difference maps changed across the
first week of treatment for each depressed subject. Lastly, a third-level,
between-subject, random effects analysis assessed whether this change in
neural activity differed between depressed patients who went on to
respond to the medication and those who did not. Baseline HAM-D score
was included as a regressor in the third-level analysis to account for the
potential influence of initial depression severity effects on both early
neural differences and overall clinical response (NB although baseline
HAM-D score did not differ between the two groups, responders and non-
responders (Table 1) and equivalent results were obtained when the
analysis was run without this covariate).
The results of all group-level analyses were corrected across the whole
brain using cluster-based thresholding with a height threshold of Z42.3
and a (whole-brain-corrected) spatial extent threshold of P= 0.05. We also
defined bilateral amygdala, bilateral insula and ACC cortex masks as a priori
regions of interest based on their sensitivity to early effects of
antidepressant drug treatments in previous studies.21 These masks were
derived from the Harvard–Oxford Cortical and Subcortical anatomical
atlases and were used in small volume correction analyses (clusters
determined by Z42.3 and a (corrected) cluster significance threshold of
P= 0.05) of the data. All reported analyses are corrected across the whole
brain unless otherwise specified (labelled as small volume correction
(SVC)). Lastly, the causal relationship between early change in fMRI signal,
change in symptom score across the first week of treatment and response
status following 6 weeks of treatment was examined using mediation
analyses. The mean change in activity within the functional clusters
identified in the previous, predictive analyses was entered as independent
variables in separate mediation analyses. In these analyses, patient
response status was entered as the dependent variable and the change
in symptom score across the first week was entered as a mediating
variable. These analyses therefore tested whether the change in fMRI
signal directly predicted future response to the antidepressant, or whether
the neural effect on treatment response was significantly mediated by the
initial change in symptoms—which would suggest that the fMRI signal
acted simply as a marker of early symptom change. A bootstrapping
procedure, as implemented by the PROCESS command for SPSS with
10 000 samples, was used to determine the confidence intervals of the
direct and indirect effects of the mediation models.
RESULTS
Clinical and demographic data
After 6 weeks’ escitalopram treatment, 22 out of 35 patients (62%)
were classified as responders. There were no differences between
responders and non-responders in terms of gender, age, baseline
depression severity, baseline trait anxiety or duration of current
episode (See Table 1, all effect sizes o0.45 Cohen’s d). However,
week 6 responders versus non-responders showed numerically
greater improvements in HAM-D score after 7 days of treatment,
although this did not reach statistical significance (t= 1.8, degree
of freedom=32.3, P= 0.08, Cohen’s d’ effect size 0.57).
fMRI data. At baseline, across all participants, fearful compared
with happy faces activated a network of areas previously
implicated in threat-relevant face processing. This included
bilateral amygdala, bilateral insula and left middle temporal gyrus
(Supplementary Table 1). Depressed patients displayed signifi-
cantly greater pretreatment activation than controls to fearful
versus happy faces in both the left insula (P= 0.02, family wise
error (FWE)-corrected, SVC) and ACC cortex (P= 0.02, FWE-
corrected, SVC; see Figure 1).
Early changes in fMRI response to fearful versus happy faces
following 7 days’ escitalopram were predictive of later clinical
response, controlling for baseline depression HAM-D severity.
Week 6 responders showed a greater decrease in neural response
to fearful versus happy faces following 7 days’ escitalopram in the
left amygdala, insula, anterior and posterior cingulate, bilateral
supramarginal gyri and bilateral thalamus (Po0.05, FWE-cor-
rected; see Table 2 and Figure 2). These clusters anatomically
overlapped with the left insula and ACC clusters identified in the
baseline comparison between depressed and control participants
described above. A formal conjunction analysis identified sig-
nificant clusters within both regions22 (ACC cluster: max Z-
value = 3.1, corrected P-value = 0.05, coordinates = 45, 70, 53;
insula cluster: max Z-value = 3.1, corrected P-value = 0.005, coordi-
nates = 64, 61, 36).
A number of additional covariates were entered into the model
to check the specificity of this effect. In this control analysis, early
change in HAM-D after 1 week, baseline trait anxiety and week 6
change in trait anxiety were entered in as regressors of no interest.
The results from this whole-brain analysis confirmed that early
change in neural response to faces of fear versus happiness
predicted clinical response even after accounting for these
possible confounds (Supplementary Table 2).
It is possible that baseline differences in neural markers of
emotional processing between responders and non-responders
might also correlate with clinical outcome at 6 weeks, and such
baseline effects could also contribute to the relationship between
change in emotional processing over 7 days of treatment and later
therapeutic response. However, we found no statistically sig-
nificant differences to fearful versus happy faces at baseline
(before treatment) in responders versus non-responders at a
whole brain level or within the regions of interest. Interestingly,
analysis of the fMRI data after 1 week of treatment alone was
sufficient to predict outcome at 6 weeks with the same network of
regions being involved (insula, thalamus, amygdala svc, thalamus
and cingulate, see Supplementary Table 3). These additional
analyses suggest that it is the ability of escitalopram to modify
emotional processing early in treatment rather than baseline
reactivity, which is related to later individual clinical response.
Lastly, we employed mediation analyses to test whether the
relationship between early change in fMRI measures and response
to treatment at week 6 was mediated by the change in depressive
symptoms across the first week—that is, whether the fMRI
measures reflected early symptom change rather than being
directly related to later response. Separate mediation analyses
were performed for each of the functional clusters identified in
Table 2. In all of these analyses, the direct effect of the fMRI signal
on response status remained significant (all Po0.012) after
controlling for the mediating effects of early symptom change.
In none of the analyses was the indirect effect (via early symptom
change) significant (all bootstrapped confidence intervals
spanned 0). In other words, mediation analysis provided additional
evidence that the observed change in fMRI signal was directly
related to the response to antidepressants and was not merely a
marker of initial symptom response.
DISCUSSION
The principal finding of our study is that changes in neural
processing of emotional information in the first week of SSRI
treatment in depressed patients are predictive of short-term
(6 weeks) therapeutic response. This early change in neural activity
preceded clinically significant changes in depressive symptoma-
tology and was not dependent on concurrent change in
symptoms at the time of the second scan. The changes in neural
activity occurred in regions which, at baseline, were differentially
activated by fearful versus happy faces and which showed
hyperactivity in depressed relative to control participants. As
An early marker of response to SSRI treatment
BR Godlewska et al
3
Translational Psychiatry (2016), 1 – 7
such, early normalisation of the neural systems responsible for
negative processing biases in depression may be an important
mechanism of antidepressant action.
The results are consistent with the cognitive neuropsychological
theory of antidepressant action, which proposes that conventional
antidepressant medications act through an early remediation of
the negative emotional biases that characterise the depressed
state.8 This theory hypothesises that treatments for depression
reduce the overwhelming influx of automatic negative cues early
in treatment, before the patient being aware of any changes in
subjective state or in the clinical symptoms of depression.
This early change in emotional processing, however, is the
mechanism that drives the later clinical response as the patient's
day-to-day environment is re-experienced through this more
positive emotional perspective.8
Neural networks involving the amygdala, insula, cingulate and
thalamus have been implicated in the generation of negative
emotional biases in depression,2,21 and our baseline comparison
between the healthy controls and depressed patients replicated
the pattern of increased response to negative versus positive faces
in parts of this circuit. Previous studies have also suggested that
hyperactivity of this circuitry in response to negative versus
positive emotional stimuli is attenuated following treatment with
antidepressants.4,7,12,23,24 In a previous, placebo-controlled, paral-
lel group study we found that that the amygdala hyperarousal
exhibited by depressed patients in response to negative faces
resolved after just 7 days of SSRI treatment and before significant
changes in the clinical state.13 The latter study is important in
showing that the effect of 7 days’ SSRI treatment on neural
responses in depressed patients cannot be attributed to the
Table 2. Prediction of clinical response from an early change in neural response to fearful compared with happy facial expressions after 7 days’
escitalopram treatment
MNI Coordinates, peak Cluster size, voxels Z-value P-value
x y z
Left amygdala/left insula –40 –22 8 2204 3.76 2.15e− 09
Anterior cingulate cortex –8 4 38 2175 3.96 2.67e−07
Left supramarginal gyrus extending to left postcentral gyrus –40 –28 32 876 3.66 0.0002
R supramarginal gyrus/right superior temporal gyrus 58 –32 2 712 3.56 0.0009
Bilateral thalamus 12 –22 10 601 3.18 0.003
Abbreviation: MNI, Montreal Neurological Institute. Whole–brain analysis at Z= 2.3 for responders versus non-responders.
Figure 1. Baseline differences in the processing of negative versus positive affective stimuli differ between depressed patients and non-
depressed control subjects. (a) Results of SVC-corrected analyses in the anterior cingulate and left insula; (b) extracted signal change from the
identified clusters. All analyses were thresholded at z= 2.3 and cluster-corrected with a FWE Po0.05. ACC, anterior cingulate cortex; FWE,
family wise error; SVC, small volume correction.
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nonspecific effects of drug administration, repeat fMRI testing or
changes in clinical state. The current investigation now provides
support for the proposal that these early changes in neural
processing of emotional information produced by antidepressant
treatment are indeed important as a mechanism of later clinical
response.
The amygdala, insula, ACC and thalamus are part of an
integrated neural system, which is important for monitoring and
affective response to emotional stimuli.25 Thalamic–amygdala
connections have been proposed to be critical for the rapid
monitoring and detection of salient stimuli for further
processing.26 In depression, increased amygdala arousal has been
suggested to create a bottom-up signal, outside of direct
conscious awareness, that biases emotional stimulus processing
across the higher cortical areas involved in a more complex
processing; this results in maladaptive perceptions of the
environment and social interactions.2 Indeed, a number of key
studies in depression indicate that the hyperactivity of amygdala
response exists even if the emotional valence of the stimulus is
processed automatically by masking conscious perception.2 An
early reduction in amygdala response to negative versus positive
stimuli with SSRI treatment may therefore not be perceived as an
immediate change in the subjective state. Instead, such a change
in implicit processing would be hypothesised to set the scene for
more adaptive perceptions of environmental stimuli, which then
influence the conscious state over time.
Besides a decrease in amygdala responsiveness, the current
study also highlights a role for early changes in the response of
the cingulate and insula to emotional stimuli. These areas form
key nodes in Mayberg’s limbic–cortical model of depression27 and
have been identified in meta-analyses of functional neuroimaging
studies as underpinning negative biases of emotional processing
in depression.28,29 The current data set adds to this body of work,
suggesting that emotion-specific modulation of response in this
area following SSRI treatment may provide an early marker of
therapeutic response.
It is of note that the difference in response to negative versus
positive facial expressions largely seems to be driven by increased
responses to happy cues rather than reduced responses to
negative cues, although both effects may be present to some
extent in areas like the amygdala. Similarly, differences between
patients and controls at baseline in response to emotional cues
seemed largely to be in response to the positive facial expressions.
These observations are consistent with a growing focus on
reduced positive processing in depression30 and also with
behavioural evidence that increased perception of happy facial
expressions rather than reduced processing of negative facial
expressions is related to later clinical outcome with antidepressant
drug treatment.31 It is difficult to draw definitive conclusions on a
pattern extracted from this kind of fMRI analysis that reveals an
overall interaction between positive versus negative cue proces-
sing; however, it suggests that a focus on the effects of boosting
Figure 2. Early changes in the processing of negative versus positive affective stimuli predict week 6 treatment response to escitalopram
across a network of areas involved in emotional processing. ACC, anterior cingulate cortex; AMG, amygdala; INS, insula; STC, superior temporal
cortex; THAL, thalamus. Whole-brain-corrected analysis at z= 2.3, responders versus non-responders.
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positive affective processing may be an important consideration in
future research studies exploring early mechanisms of treatment
response in depression.
In addition to the neural changes described above, 7 days’
treatment with escitalopram was associated with some reduction
in HAM-D scores, and this was numerically greater in later clinical
responders. This raises the possibility that the change in neural
activity found in the second scan in subsequent treatment
responders might be secondary to this early improvement,32
rather than the neural changes leading to the subsequent clinical
response. However, when this initial change in HAM-D score was
accounted for in our statistical model, the early changes in neural
response were still predictive of the therapeutic outcome. A
secondary mediation analysis further suggested that early
changes in neural response to emotional information mediate
later clinical change, independent from any influence of early
mood change. Therefore, early change in clinical symptoms does
not seem to be driving the prediction provided by changes in
emotional processing response.
Previous studies have identified differences in baseline (pre-
treatment) neural response to emotional material as a predictor of
likely clinical response. In particular, increased perfusion and
response in the rostral cingulate have been related to increased
likelihood of response to antidepressant treatment.33 A recent PET
study further suggested that basal perfusion of the insula may
serve as a specific biomarker for response to drug versus
psychological treatment,34 with increased perfusion related to a
higher likelihood of remission with SSRI therapy, and the converse
being true for cognitive behavioural therapy. However, the current
pattern of results suggests that early change in neural response
following SSRI treatment may be more sensitive to clinical
response than baseline measures in fMRI. This approach has the
potential to test the specific effects of a particular treatment at a
given dose and time in patients at an early stage of the
intervention.
Our findings have a number of clinical implications. First, they
suggest that rapid change in emotional processing circuitry is
related to clinical effectiveness of a particular treatment. As such,
emotional processing models may usefully be applied in the drug-
discovery programmes to facilitate decision-making about novel
treatments in development. Critically, we have found early
positive biases in emotional processing across antidepressant
classes, including SSRIs, norepinephrine reuptake inhibitors and
atypical antidepressants such as mirtazapine10,11,35 as well as
treatments with novel mechanisms of action such as the
N-methyl-D-aspartate receptor antagonist AZD6765.36 Second, as
many patients do not respond to the first-line treatment with a
given agent and waiting time for response can compound
the delay in effective treatment, an early marker that could be
used to tailor treatment in an individual would have significant
advantages. It is also worth noting that relevant fMRI changes in
emotional processing can be identified after single doses of
antidepressant drugs in healthy volunteers.8 This raises the
intriguing possibility that assessing the effect of single doses
of medication in depressed patients might also have
predictive value.
Future studies should, therefore, assess whether this early
signature of antidepressant drug action can be used to predict
response on an individual-patient level, using a priori defined
neural and/or behavioural criteria and in a larger cohort of
patients. It will also be necessary to examine whether these early
changes in emotional processing predict placebo response, that is,
function as a general marker of improvement rather than a
specific drug-induced mechanism. Our study was limited by the
absence of a placebo control condition to test this hypothesis,
although in our earlier work we have found little influence of
placebo treatment on emotional processing.13
In summary, this study provides the key evidence that, following
the initiation of antidepressant treatment, early changes in the
activity of neural systems responsible for emotional processing
mediate later clinical response. These observations may be relevant
to the development of improved therapeutic approaches to
depression as well as for the early detection of clinical response.
CONFLICT OF INTEREST
CJH has received consultancy fees from P1vital, Lundbeck, Servier, Eli-Lilly. She is a
company director of Oxford Psychologists Ltd and holds shares in P1vital. MB is
employed on a part time basis by P1vital. PJC has been a member of a Lundbeck
advisory board for the last 3 years. The remaining authors declare no conflict of
interest.
ACKNOWLEDGMENTS
The study was funded by the MRC programme grant to PJC (G0701421).
REFERENCES
1 Beck AT. The evolution of the cognitive model of depression and its neurobio-
logical correlates. Am J Psychiatry 2008; 165: 969–977.
2 Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive
model of depression. Nat Rev Neurosci 2011; 12: 467–477.
3 Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr 2013; 18:
139–149.
4 Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased
amygdala response to masked emotional faces in depressed subjects resolves
with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651–658.
5 Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ et al. A
differential pattern of neural response toward sad versus happy facial expressions
in major depressive disorder. Biol Psychiatry 2005; 57: 201–209.
6 Suslow T, Konrad C, Kugel H, Rumstadt D, Zwitserlood P, Schöning S. Automatic
mood–congruent amygdala responses to masked facial expressions in major
depression. Biol Psychiatry 2010; 67: 155–160.
7 Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC. Relationship between
amygdala responses to masked faces and mood state and treatment in major
depressive disorder. Arch Gen Psychiatry 2010; 67: 1128–1138.
8 Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to
work? A cognitive neuropsychological model of antidepressant drug action. Br J
Psychiatry 2009; 195: 102–108.
9 Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative
affective perception and memory in healthy volunteers following selective serotonin
and norepinephrine reuptake inhibition. Am J Psychiatry 2004; 161: 1256–1263.
10 Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug
treatment modifies the neural processing of nonconscious threat cues. Biol Psy-
chiatry 2006; 59: 816–820.
11 Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. Short–term anti-
depressant treatment and facial processing. Functional magnetic resonance
imaging study. Br J Psychiatry 2007; 190: 531–532.
12 Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J et al. Attenuation of
the neural response to sad faces in major depression by antidepressant treat-
ment: a prospective, event-related functional magnetic resonance imaging study.
Arch Gen Psychiatry 2004; 61: 877–889.
13 Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short–term SSRI
treatment normalises amygdala hyperactivity in depressed patients. Psychol Med
2012; 42: 2609–2617.
14 Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM–
1 V (SCID). Biometrics Research, New York State Psychiatric Institute: New York,
NY, USA, 1995.
15 Hamilton M. A rating scale for depression. J Neurol Neurosurgery 1960; 23: 56–62.
16 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring
depression. Arch Gen Psychiatry 1961; 4: 561–571.
17 Spielberger CD. State-Trait Anxiety Inventory: Bibliography. 2nd edn, Consulting
Psychologists Press: Palo Alto, CA, USA, 1989.
18 Angst J, Delini–Stula A, Stabl M, Stassen HH. Is a cutoff score a suitable measure of
treatment outcome in short–term trials in depression? A methodological meta–
analysis. Hum Psychopharmacol 1993; 8: 311–317.
19 Costafreda SG, Brammer MJ, David AS, Fu CH. Predictors of amygdala activation
during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI
studies. Brain Res Rev 2008; 58: 57–70.
An early marker of response to SSRI treatment
BR Godlewska et al
6
Translational Psychiatry (2016), 1 – 7
20 Jenkinson M, Beckmann CF, Behrens T, Woolrich M, Smith S. FSL. Neuroimage
2012; 62: 782–790.
21 Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacol-
ogy 2010; 35: 192–216.
22 Nichols T, Brett M, Andersson J, Wager T, Poline JB. Valid conjunction inference
with the minimum statistic. Neuroimage 2005; 25: 653–660.
23 Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P. Brain
effects of antidepressants in major depression: a meta–analysis ofemotional
processing studies. J Affect Disord 2011; 130: 66–74.
24 Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective
processing in depressed patients treated with venlafaxine. Am J Psychiatr 2003;
160: 64–75.
25 Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II:
implications for major psychiatric disorders. Biol Psychiatry 2003; 54: 515–528.
26 Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001; 6:
13–34.
27 Mayberg HS. Limbic–cortical dysregulation: a proposed model of depression.
J Neuropsychiatry Clin Neurosci 1997; 9: 471–481.
28 Diener C, Kuehner C, Brusniak W, Ubl B, Wessa M, Flor H. A meta–analysis of
neurofunctional imaging studies of emotion and cognition in major depression.
Neuroimage 2012; 61: 677–685.
29 Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. Functional
neuroimaging of major depressive disorder: a meta-analysis and new integration
of base line activation and neural response data. Am J Psychiatry. 2012; 169:
693–70.
30 Lewis G, Kounali D, Button KS, Duffy L, Wiles NJ, Munafò MR et al. Reduced
Positive Bias in People with Depression: Evidence for Depressive Realism in a
Prospective Longitudinal Cohort (in submission to Lancet Psychiatru).
31 Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM. The effect of
serotonergic and noradrenergic antidepressants on face emotion processing in
depressed patients. J Affect Disord. 2009; 118: 87–93.
32 Taylor MJ. Rapid onset of true antidepressant action. Curr Psychiatry Rep 2007; 9:
475–479.
33 Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of
treatment response. Neuropsychopharmacology 2011; 36: 183–206.
34 McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR
et al. Toward a neuroimaging treatment selection biomarker for major depressive
disorder. JAMA Psychiatry 2013; 70: 821–829.
35 Rawlings NB, Norbury R, Cowen PJ, Harmer CJ. A single dose of mirtazapine
modulates neural responses to emotional faces in healthy people. Psycho-
pharmacology (Berl) 2010; 212: 625–634.
36 Harmer CJ, Rylands R, Parsons L, Dawson G, Deakin B, Goodwin et al. Comparative
Antidepressant Mechanisms of Lanicemine And Ketamine 2: Effects on Emotion
Processing (in submission).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2016
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
An early marker of response to SSRI treatment
BR Godlewska et al
7
Translational Psychiatry (2016), 1 – 7
